Three European countries are all heading towards different forms of supplementary insurance, which will change the private healthcare sector and the balance of power between insurers and healthcare providers.
GHX, the world's leading eCommerce and exchange platform for medtech products, has been bought from a consortium of 20 suppliers and providers by tech-focused US private equity house Thoma Bravo. What ramifications will this have for transparency in procurement? We talk to Bruce Johnson, GHX CEO, and look at the price of the deal.
Shares in Espirito Santo Saude, the second-largest Portuguese hospital group, slipped six cents to €3.14 after trading started on Feb 12. The IPO, which raised €150m - of which €25m will go to the company for further expansion - was at the low end of the initial price range. Many will be watching ESS with eagle eyes. It is the first substantial IPO of a European hospital group since 2001. So what does the valuation tell us?
Who would ever feel sorry for big reagent manufacturers - Abbott, Roche and Siemens? Well, from what we hear, the big lab groups really are squeezing them dry.
How is the German hospital system changing? Will the private sector play a larger role? Who better to ask than Boris Augurzky, at the Rheinisch-Westfälisches Institut
für Wirtschaftsforschung, author of an annual report on the German hospital sector?
Over the last three years, many people in the private sector have indicated that the real growth in France will come from the rise of supplementary insurance and the retreat of the state. “France will become a little more like America,” they tell us. The rise of supplementary insurance will give the private sector, from dentists to hospitals, the space they need to breathe. But is this really true?
Russian private equity house Venture Investments & Yield Management (VIYM) has just bought a substantial stake in Semeiny Doktor, a Moscow chain of family medical clinics. We talk to VIYM’s Sergey Volchenkov about the deal and the Russian outpatient market.
Mount Carmel, the last private maternity hospital in Ireland, has been put into liquidation by administrators. What does this tell us about the health of healthcare in the country?
The Proton Therapy Center (PTC) in Prague, one of the very few private proton centres in Europe, is the source of a dispute between Erste Bank, which lent it CZK 4.2bn (€153m) and VZP, the largest Czech insurer. We look at what is going on, and at the business model behind it.
The vast majority of bribes paid by citizens in Europe have to do with access to healthcare, according to an EU anti-corruption report. Healthcare and pharma businesses in Europe are also the most likely of any industry, with 77% agreeing, to think that corruption is widespread in their country. The report puts the total cost of corruption in the EU at €120bn - a little less than the annual EU budget. We look at the underlying numbers.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
